NextCure (NXTC) Return on Sales (2019 - 2020)
NextCure (NXTC) posted quarterly Return on Sales of 0.06% for Q4 2020, little changed year-over-year from 0.06% in Q1 2020, and down 12.62% quarter-over-quarter from 0.06% in Q3 2020.
NextCure (NXTC) Return on Sales (2019 - 2020) Analysis & Trends
NextCure's Return on Sales history runs 2 years deep, the most recent figure standing at 0.06% for Q4 2020.
- In Q4 2020, Return on Sales changed 0.0% year-over-year to 0.06%; the TTM figure through Dec 2020 stood at 0.06% (up 13.0% YoY), while the FY2020 annual figure was 0.03%, up 20.0% from the prior year.
- Return on Sales for Q4 2020 stood at 0.06%, down from 0.06% in the prior quarter.
- The five-year high for Return on Sales was 0.03% in Q1 2020, with the low at 0.41% in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROS (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 0.00% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 0.00% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 0.00% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -0.05% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 0.00% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 0.00% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 0.00% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 0.00% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.00% |
| 10 | NextCure | 33.72 Mn | 33.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -0.06% |
| Sep 30, 2020 | -0.06% |
| Jun 30, 2020 | -0.07% |
| Mar 31, 2020 | -0.03% |
| Dec 31, 2019 | -0.06% |
| Sep 30, 2019 | -0.41% |
| Jun 30, 2019 | -0.21% |
| Mar 31, 2019 | -0.13% |